Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor

被引:53
作者
Schaufele, F
Chang, CY
Liu, WQ
Baxter, JD
Nordeen, SK
Wan, YH
Day, RN
McDonnell, DP
机构
[1] Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[3] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA
[4] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA
[5] Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA
[6] Univ Virginia, Hlth Sci Ctr, Natl Sci Fdn, Ctr Biol Timing,Dept Med, Charlottesville, VA 22908 USA
[7] Univ Virginia, Hlth Sci Ctr, Natl Sci Fdn, Ctr Biol Timing,Dept Cell Biol, Charlottesville, VA 22908 USA
关键词
D O I
10.1210/me.14.12.2024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ligand binding to estrogen receptor (ER) is presumed to regulate the type and timing of ER interactions with different cofactors. Using fluorescence microscopy in living coils, we characterized the recruitment of five different green fluorescent protein (GFP)-labeled ER-interacting peptides to the distinct subnuclear compartment occupied by blue fluorescent protein (BFP)-labeled ER alpha. Different ligands promoted the recruitment of different peptides. One peptide was recruited in response to estradiol (E-2), tamoxifen, raloxifene, or ICI 182,780 incubation whereas other peptides were recruited specifically by E-2 or tamoxifen. Peptides containing different sequences surrounding the ER-interacting motif LXXLL were recruited with different time courses after E-2 addition. Complex temporal kinetics also were observed for recruitment of the full-length, ER cofactor glucocorticoid receptor-interacting protein 1 (GRIP1); rapid, E-2-dependent recruitment of GRIP1 was blocked by mutation of the GRIP1 LXXLL motifs to LXXAA whereas slower E-2 recruitment persisted for the GRIP1 LXXAA mutant. This suggested the presence of multiple, temporally distinct GRIP 1 recruitment mechanisms. E-2 recruitment of GRIP1 and LXXLL peptides was blocked by coincubation with excess ICI 182,780. In contrast, preformed E-2/ER/GRIP1 and E-2/ER/LXXLL complexes were resistant to subsequent ICI 182,780 addition whereas ICI 182,780 dispersed preformed complexes containing the GRIP1 LXXAA mutant. This suggested that E-2-induced LXXLL binding altered subsequent ligand/ER interactions. Thus, alternative, ligand-selective recruitment and dissociation mechanisms with distinct temporal sequences are available for ERa action in vivo.
引用
收藏
页码:2024 / 2039
页数:16
相关论文
共 50 条
[1]  
Assikis V J, 1997, Oncology (Williston Park), V11, P21
[2]  
Bode J, 2000, CRIT REV EUKAR GENE, V10, P73
[3]   Nuclear structure, gene expression and development [J].
Brown, K .
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1999, 9 (3-4) :203-212
[4]   Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758
[5]   NUCLEAR FACTOR RIP140 MODULATES TRANSCRIPTIONAL ACTIVATION BY THE ESTROGEN-RECEPTOR [J].
CAVAILLES, V ;
DAUVOIS, S ;
LHORSET, F ;
LOPEZ, G ;
HOARE, S ;
KUSHNER, PJ ;
PARKER, MG .
EMBO JOURNAL, 1995, 14 (15) :3741-3751
[6]  
Chang CY, 1999, MOL CELL BIOL, V19, P8226
[7]   Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase [J].
Chen, HW ;
Lin, RJ ;
Xie, W ;
Wilpitz, D ;
Evans, RM .
CELL, 1999, 98 (05) :675-686
[8]   Activities in Pit-1 determine whether receptor interacting protein 140 activates or inhibits Pit-1 nuclear receptor transcriptional synergy [J].
Chuang, FM ;
West, BL ;
Baxter, JD ;
Schaufele, F .
MOLECULAR ENDOCRINOLOGY, 1997, 11 (09) :1332-1341
[9]   Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer [J].
Colditz, GA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (11) :814-823
[10]   The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].
Cummings, SR ;
Eckert, S ;
Krueger, KA ;
Grady, D ;
Powles, TJ ;
Cauley, JA ;
Norton, L ;
Nickelsen, T ;
Bjarnason, NH ;
Morrow, M ;
Lippman, ME ;
Black, D ;
Glusman, JE ;
Costa, A ;
Jordan, VC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197